Coverage
Filings
| Filing | Date |
|---|---|
| Blenrep for 2L+ multiple myeloma approved in Japan | 19 May 2025 |
| Transaction in Own Shares | 16 May 2025 |
| Transaction in Own Shares | 15 May 2025 |
| Transaction in Own Shares | 14 May 2025 |
| GSK to acquire efimosfermin | 14 May 2025 |
| Transaction in Own Shares | 13 May 2025 |
| Update on belrestotug development programme | 13 May 2025 |
| Director/PDMR Shareholding | 13 May 2025 |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 12 May 2025 |
| Block listing Interim Review | 12 May 2025 |
| Transaction in Own Shares | 9 May 2025 |
| Transaction in Own Shares | 8 May 2025 |